Detalhe da pesquisa
1.
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.
JTO Clin Res Rep
; 2(2): 100114, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589984
2.
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Clin Cancer Res
; 27(11): 3094-3105, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33558422
3.
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.
Clin Cancer Res
; 27(24): 6677-6686, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34598946
4.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
J Clin Oncol
; 38(32): 3763-3772, 2020 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32795228
5.
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Clin Cancer Res
; 26(11): 2487-2496, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32086346